Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Omidenepag Isopropyl. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER2 known ✓ | P43116 | 20/20 | 1.00 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.80 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Omidenepag Isopropyl SCHEMBL29375346 | 1.00 | PTGER2 (1.00) | PTGER2PTGER4 | |
| Omidenepag Isopropyl SCHEMBL15414827 | 1.00 | PTGER2 (1.00) | PTGER2PTGER4 | |
| Omidenepag SCHEMBL533632 | 0.89 | PTGER2 (1.00) | PTGER2PTGER4 | |
| Omidenepag SCHEMBL29565501 | 0.89 | PTGER2 (1.00) | PTGER2PTGER4 | |
| Omidenepag SCHEMBL30433956 | 0.89 | PTGER2 (1.00) | PTGER2PTGER4 | |
| Omidenepag SCHEMBL533245 | 0.89 | PTGER2 (1.00) | PTGER2PTGER4 | |
| SCHEMBL533446 | 0.88 | PTGER2 (0.78) | PTGER2PTGER4 | |
| SCHEMBL17347610 | 0.87 | PTGER2 (0.77) | PTGER2 | |
| SCHEMBL22107549 | 0.87 | PTGER2 (0.77) | PTGER2PTGER4 | |
| SCHEMBL15414829 | 0.85 | PTGER2 (0.74) | PTGER2PTGER4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4731194-A1 | MATERIALS AND METHODS FOR MITIGATING THE PRESENCE OF NITROSAMINES IN PACKAGING USING AN ACTIVE AGENT | CSP Technologies, Inc. (US) | 2026-04-29 | — | — | EP | disclosed |
| WO-2025264260-A1 | MATERIALS AND METHODS FOR MITIGATING THE PRESENCE OF NITROSAMINES IN PACKAGING USING AN ACTIVE AGENT | CSP TECHNOLOGIES, INC. (US) | 2025-12-26 | — | — | WO | disclosed |
| US-12290511-B2 | Pharmaceutical preparation containing pyridyl aminoacetic acid compound | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2025-05-06 | — | — | US | disclosed |
| WO-2024263560-A1 | MATERIALS AND METHODS FOR MITIGATING THE PRESENCE OF NITROSAMINES IN PACKAGING USING AN ACTIVE AGENT | CSP TECHNOLOGIES, INC. (US) | 2024-12-26 | — | — | WO | disclosed |
| US-20230277515-A1 | PHARMACEUTICAL PREPARATION CONTAINING PYRIDYL AMINOACETIC ACID COMPOUND | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2023-09-07 | — | — | US | disclosed |
| US-11666563-B2 | Pharmaceutical preparation containing pyridyl aminoacetic acid compound | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2023-06-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12290511-B2 | Pharmaceutical preparation containing pyridyl aminoacetic acid compound | PTGIS, AASDHPPT, AGT | PTGER2 121/4885PTGER4 131/4885 |
| US-11666563-B2 | Pharmaceutical preparation containing pyridyl aminoacetic acid compound | PTGIS, AASDHPPT, AGT | PTGER2 121/4885PTGER4 131/4885 |
| US-20230277515-A1 | PHARMACEUTICAL PREPARATION CONTAINING PYRIDYL AMINOACETIC ACID COMPOUND | PTGIS, AASDHPPT, AGT | PTGER2 121/4885PTGER4 131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.